|
시장보고서
상품코드
2077525
다사티닙 약물 시장 : 유형별, 적응증별, 유통 채널별, 지역별Dasatinib Drugs Market, By Type, By Indication, By Distribution Channel, By Geography |
||||||
다사티닙 약물 시장은 2026년에 17억 4,820만 달러 규모가 될 것으로 추정되고 있어 2033년에 26억 6,350만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 6.2%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 17억 4,820만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년까지 예측 기간 CAGR : | 6.20% | 2033년 시장 규모 예측 : | 26억 6,350만 달러 |
다사티닙은 특정 유형의 암 치료 방식에 혁명을 일으킨 유망한 티로신 키나제 억제제입니다. 당초, 만성 골수성 백혈병(CML) 및 필라델피아 염색체 양성 급성 림프구성 백혈병(Ph+ALL)에 대한 표적 치료제로 개발된 다사티닙은 BCR-ABL 단백질을 특이적으로 표적으로 삼아 그 활성을 억제함으로써 암세포의 증식을 억제합니다. 이러한 뚜렷한 효능 덕분에, 다사티닙은 이러한 악성 종양 환자들의 예후를 크게 개선하고 생존율을 높였습니다. 또한, 다사티닙은 SRC 계열 키나아제를 포함한 다른 티로신 키나아제에 대해서도 억제 작용을 나타내며, 그 적용 가능성을 다양한 종양으로 확대되고 있습니다. 다사티닙은 유망한 치료 옵션이지만, 부작용이 전혀 없는 것은 아니므로 신중한 모니터링과 관리가 필요합니다. 현재 진행 중인 조사 및 임상 검사에서는 병용 요법에서 다사티닙의 가능성이 탐구되고 있으며, 이는 암 치료 전략의 추가적인 발전을 위한 길을 열어주고 있습니다.
시장 역학
암 유병률 증가, 양호한 임상 결과, 승인 적응증의 확대가 예측 기간 동안 전 세계 다사티닙 약물 시장의 성장을 견인할 것으로 예측됩니다. 또한, 표적 치료제의 개발 역시 예측 기간 동안 전 세계 다사티닙 약물 시장의 성장을 견인할 것으로 전망됩니다. 신흥 시장 진출, 병용 요법, 소아 적응증, 제네릭 의약품 개발이 예측 기간 동안 전 세계 다사티닙 약물 시장의 성장 기회를 창출할 것으로 예측됩니다.
그러나 높은 치료비, 엄격한 규제 요건, 잠재적인 부작용, 내성 발생 등이 예측 기간 동안 다사티닙 시장의 성장을 저해할 것으로 예측됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 다사티닙 약물 시장의 주요 기업 프로파일을 발표하고 있습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대, 마케팅 전략에 관해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 다사티닙 약물 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 다사티닙 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 다사티닙 약물 시장 : 유형별, 2021-2033년
제5장 다사티닙 약물 시장 : 적응증별, 2021-2033년
제6장 다사티닙 약물 시장 : 유통 채널별, 2021-2033년
제7장 다사티닙 약물 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
JHS 26.07.13Dasatinib Drugs Market is estimated to be valued at USD 1,748.2 Mn in 2026 and is expected to reach USD 2,663.5 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,748.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.20% | 2033 Value Projection: | USD 2,663.5 Mn |
Dasatinib is a potential tyrosine kinase inhibitor that has revolutionized the treatment landscape for certain types of cancer. Initially developed as a targeted therapy for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), dasatinib specifically targets and inhibits the BCR-ABL protein, suppressing the growth and proliferation of cancer cells. With remarkable efficacy, dasatinib has significantly improved outcomes and increased survival rates in patients with these malignancies. Moreover, dasatinib exhibits inhibitory effects on other tyrosine kinases, including SRC family kinases, broadening its potential application to various tumors. While dasatinib offers a promising therapeutic option, it is not without side effects, necessitating careful monitoring and management. Ongoing research and clinical trials are exploring the potential of dasatinib in combination therapies, paving the way for further advancements in cancer treatment strategies.
Market Dynamics:
The increasing prevalence of cancer, favorable clinical outcomes, and expansion of approved indications are anticipated to drive the growth of the global dasatinib drugs market over the forecast period. Moreover, the development of targeted therapies is also expected to boost the growth of the global dasatinib drugs market over the forecast period. Expansion into emerging markets, combination therapies, pediatric indications, and the development of generic versions are expected to create growth opportunities for the global dasatinib drugs market growth during the forecast period.
However, the high cost of treatment, stringent regulatory requirements, potential adverse effects, the development of resistance are expected to hamper the growth of the dasatinib drugs market over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dasatinib drugs market based on the following parameters - company highlights, product portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bristol-Myers Squibb Company, MSN Labs, Lupin, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Hetero Labs, MANUS AKTTEVA BIOPHARMA LLP, Alembic Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., and Zhejiang Hisun Pharma
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global dasatinib drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dasatinib drugs market
Detailed Segmentation:
- Dasatinib Drugs Market, By Type (Revenue, USD Mn, 2021 - 2033)
- 20 mg
- 50 mg
- 70 mg
- Dasatinib Drugs Market, By Indication (Revenue, USD Mn, 2021 - 2033)
- Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Others
- Dasatinib Drugs Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Bristol-Myers Squibb
- MSN Labs
- Lupin
- Dr. Reddy's Laboratories
- Hetero Labs
- MANUS AKTTEVA BIOPHARMA LLP
- Alembic Pharma
- JINLAN Pharm-Drugs Technology Co., Ltd.
- Reddy's Laboratories
- Zhejiang Hisun Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Type
- Market Snippet, By Indication
- Market Snippet, By Distribution channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Increasing prevalence of cancer
- Restraints
- Increasing product recall
- Opportunities
- Expansion into emerging markets
- Combination therapies
- Pediatric indications
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Dasatinib Drugs Market, By Type, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- 20 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- 50 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- 70 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
5. Dasatinib Drugs Market, By Indication, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Chronic Myeloid Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Acute Lymphoblastic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
6. Dasatinib Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
7. Dasatinib Drugs Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022 -2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Mn)
- North Africa
- South Africa
- Central Africa
8. Competitive Landscape
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MSN Labs
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hetero Labs
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharma,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- JINLAN Pharm-Drugs Technology Co., Ltd.,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zhejiang Hisun Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
- Company Highlights
9. Section
- Research Methodology
- About us
